KAYS: Kaya Holdings, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1.25
Enterprise Value ($M) 8.11
Book Value ($M) -18.16
Book Value / Share -0.44
Price / Book -0.07
NCAV ($M) -18.34
NCAV / Share -0.44
Price / NCAV -0.07

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -13.43
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.01
Current Ratio 0.01

Balance Sheet (mrq) ($M)
Current Assets 0.09
Assets 0.27
Liabilities 18.43
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)
Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-22 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter ended September 30, 2024 [ ] TRANSITION REPORT PURSUANT TO SECTION
2024-08-19 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment Number 1 to Form 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter ended June 30, 2024 [ ] TRANSITI
2024-08-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter ended June 30, 2024 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 O
2024-08-01 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 to Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter ended March 31, 2024 ☐ TRANSITION REP
2024-08-01 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 to Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTIONS 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 ☐ TRA
2024-05-16 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter ended March 31, 2024 [ ] TRANSITION REPORT PURSUANT TO SECTION 13
2024-04-16 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

(click for more detail)

Similar Companies
IVBT – Innovation1 Biotech Inc. IVEVF – Inventiva S.A.
KANT – Kineta, Inc. KBYPF – Kobayashi Pharmaceutical Co., Ltd.
KLDO – Kaleido Biosciences, Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: Kaya Holdings